

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Effect of whole-grain barley on the human fecal microbiota and metabolome

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Angelis, M.D., Montemurno, E., Vannini, L., Cosola, C., Cavallo, N., Gozzi, G., et al. (2015). Effect of whole-grain barley on the human fecal microbiota and metabolome. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 81(22), 7945-7956 [10.1128/AEM.02507-15].

Availability:

This version is available at: <https://hdl.handle.net/11585/522084> since: 2015-12-03

Published:

DOI: <http://doi.org/10.1128/AEM.02507-15>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

This is the final peer-reviewed accepted manuscript of:

Effect of Whole-Grain Barley on the Human Fecal Microbiota and Metabolome

Authors: Maria De Angelis, Eustacchio Montemurno, Lucia Vannini, Carmela Cosola, Noemi Cavallo, Giorgia Gozzi, Valentina Maranzano, Raffaella Di Cagno, Marco Gobetti, Loreto Gesualdo

Applied and Environmental Microbiology Vol. 81, No. 22

<https://journals.asm.org/doi/10.1128/AEM.02507-15>

The final published version is available online at:

<https://doi.org/10.1128/AEM.02507-15>

Rights / License:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)

When citing, please refer to the published version.

1 **The role of whole-grain barley on human fecal microbiota and metabolome**

2

3

4 **Maria De Angelis^a, Eustachio Montemurno^b, Lucia Vannini^{c,d}, Carmela Cosola^b, Noemi**

5 **Cavallo^a, Giorgia Gozzi^c, Valentina Maranzano^b, Raffaella Di Cagno^a, Marco Gobbetti^{a#},**

6 **Loreto Gesualdo^b**

7 ^aDepartment of Soil, Plant and Food Sciences, University of Bari Aldo Moro, Bari, Italy;

8 ^bDepartment of Emergency and Organ Transplantation, Nephrology Unit - University of Bari Aldo
9 Moro, Bari, Italy;

10 ^cDepartment of Agricultural and Food Sciences, University of Bologna, Bologna, Italy;

11 ^dInter-departmental Centre for Industrial Agri-Food Research, University of Bologna, Cesena, Italy

12

13

14 *Running title: Whole-grain barley and human fecal microbiota*

15

16 #Corresponding author: Marco Gobbetti, Department of Soil, Plant and Food Sciences, University
17 of Bari Aldo Moro, via Amendola 165/a, 70126 Bari, Italy, Tel.: +39.080.5442946; fax:
18 +39.080.5442911. E-mail address: marco.gobbetti@uniba.it

19

20

21 **ABSTRACT**

22 This study aimed at comparing the fecal microbiota and metabolome of 26 healthy subjects before
23 (HS) and after (HSB) two months of diet intervention based on the administration of durum wheat
24 flour and whole-grain barley Pasta containing the minimum recommended daily intake (3 g) of
25 barley β -glucans. Metabolically active bacteria were analyzed through pyrosequencing of the gene
26 16S rRNA and community-level catabolic profiles. Pyrosequencing data showed that
27 *Clostridiaceae* (*Clostridium orbiscindens*, *Clostridium* sp.), *Roseburia hominis*, and *Ruminococcus*
28 sp. increased while other *Firmicutes* and *Fusobacteria* decreased in HSB compared to HS fecal
29 samples. Community-level catabolic profiles were the lowest in HSB. Compared to HS, cultivable
30 lactobacilli increased in HSB fecal samples while *Bacteroides*, *Porphyromonas* and *Prevotella*,
31 *Enterobacteriaceae*, total coliforms, and *Pseudomonas*, *Alcaligenes* and *Aeromonas* decreased.
32 Metabolome analyses were performed using amino acid analyzer and gas-chromatography mass
33 spectrometry-solid-phase micro-extraction. A marked increase of short chain fatty acids (SCFA)
34 such as 2-methyl-propanoic acid, acetic, butyric and propionic acids was found in HSB with respect
35 to HS fecal samples. Durum wheat flour and whole-grain barley Pasta containing 3% of barley β -
36 glucans appeared to be effective in the modulation of the composition and the metabolic pathways
37 of the intestinal microbiota, leading to an increased level of SCFA.

38

39 INTRODUCTION

40 Whole-grain barley and oat, and some dry-milled bran grain products were authorized to be used
41 according to the health claim “decrease the risk of coronary heart disease” by Food and Drug
42 Administration (1, 2). Whole barley and oat flours contain β -glucans which are soluble dietary
43 fibers. European Food Safety Authority recognized that the “regular consumption of oat β -glucans
44 can actively lower/reduce blood LDL-cholesterol and total cholesterol (3). In addition to reduction
45 of cholesterol, the positive associations between the consumption of β -glucans and the
46 reduction/prevention of cardiovascular diseases, and reduction of glycemia, insulin resistance and
47 metabolic syndrome were well documented (4, 5). The minimum dose of 3 g/day of β -glucans is
48 recommended to get positive effects on human health (1, 3, 6).

49 Several mechanisms were described for explaining the hypocholesterolemic effect of β -glucans: (i)
50 increased viscosity at the level of the small intestine and, consequently, slowed gastric emptying,
51 digestion, and absorption of molecules, including glucose, dietary cholesterol and bile acids (7, 8);
52 (ii) decreased enter-hepatic bile acids by binding at intestinal level with subsequent increased use of
53 cholesterol for bile acids synthesis (9, 10); (iii) reduced synthesis of hepatic cholesterol due to the
54 improved insulin sensitivity (10, 11); and iv) inhibited hepatic synthesis of cholesterol by acetate
55 and propionate, which are produced by colonic fermentation of β -glucans (12, 13). Saccharolytic
56 and proteolytic fermentations are the major fermentation processes, which are carried-out by
57 metabolically active microbes at the colon level (14). Saccharolytic fermentation was associated
58 with the synthesis of short-chain fatty acids (SCFA) (acetate, propionate and butyrate), intermediate
59 metabolites such as succinate, acrylate, lactate, formate and ethanol, and small final molecules
60 (hydrogen, methane and carbon dioxide) (15). Proteolytic fermentation was associated with the
61 synthesis of SCFA (acetate, propionate and butyrate) and branched-chain fatty acid (BCFA) (iso-
62 butyric, iso-valeric and 2-methylbutyric acids), free amino acids (FAA) and some potentially toxic
63 metabolites (phenols, indoles, ammonia and amines) (14, 16, 17). The type of colonic fermentation
64 is mainly depends on the type of microbiota and fermentable substrate availability (17). Based on

65 the key role for human healthy, the intestinal microbiota was acknowledged as a metabolic organ
66 (18). The major part of the current research on novel functional foods is moved towards the
67 selection and characterization of prebiotics (e.g. inulin, fructo-oligosaccharides and galacto-
68 oligosaccharides), which are not digested by human gastrointestinal enzymes but selectively
69 stimulate the growth and/or activity of GRAS bacteria that may improve host health (19). Indeed, a
70 prebiotic effect of β -glucans towards the intestinal microbiota was also hypothesized (5). In
71 particular, the positive effect of β -glucans on the growth of beneficial intestinal lactobacilli and
72 bifidobacteria was shown by *in vitro* studies (20, 21) and animal experiments (22, 23).
73 Nevertheless, other studies that also used animal models did not show significant effects of β -
74 glucans on lactobacilli and/or bifidobacteria (24, 25). Unfortunately, human clinical challenges that
75 have dealt with the prebiotic effect of β -glucans are rather scarce. Barley β -glucans increased the
76 cell density of colonic bifidobacteria on older healthy subjects (26). A pilot study with
77 polypectomized patients showed no significant effect of β -glucans on the fecal microbiota and the
78 concentration of SCFA (27). The evidence that β -glucans positively influence the human intestinal
79 microbiota is still insufficient or difficult to interpret, and additional studies are needed to fill this
80 gap (5).

81 This study compared the fecal microbiota and metabolome of healthy subjects before (HS) and after
82 (HSB) two months of daily administration of durum wheat flour and whole-grain barley Pasta
83 containing the minimum recommended intake (3 g) of β -glucans. The fecal microbiota was
84 characterized through integrated approaches, which were based on culture-independent and -
85 dependent methods.

86 MATERIALS AND METHODS

87 Subjects

88 The study was carried out in accordance with the Helsinki Declaration (IV Adaptation) and
89 European Guidelines for Good Clinical Practice. The protocol of the study was approved by the

90 Institutional Review Board of the Azienda Ospedaliero-Universitaria Consorziale Policlinico of
91 Bari, Italy (Authorization nr. 1570/2014). Written consents were obtained from all volunteers. One
92 groups of Caucasian HS (15 female and 11 male), aged between 28 and 57 years, were enrolled in
93 the study (Table 1). Exclusion criteria were history of gastro-intestinal disease, diabetes,
94 cardiovascular diseases, hyperlipidemia and consume of alcohol. Volunteers were not treated with
95 antibiotics and/or functional foods (probiotics and/or prebiotics) for at least three months before
96 recruitment and sampling.

97 **Feeding regime**

98 Pasta Granoro Cuore Mio (Granoro srl, Corato, BA) was used in this study. Pasta was made by
99 using a mixture of durum wheat flour (75%) and whole-grain barley flour (25%). The gross
100 composition of Pasta Granoro Cuore Mio was as follows: moisture, 11%; protein (N x 5.70), 11%
101 of dry matter; carbohydrate, 69% of dry matter; fat, 2% of dry matter; total fibres and β -glucans, 7%
102 and 3% of dry matter, respectively. Before starting with the administration of 100 g Pasta Granoro
103 Cuore Mio Pasta containing 3 g of barley β -glucans (Granoro srl), each volunteer was instructed to
104 follow the usual diet, including 100 g of Pasta every day for two months. Before and after the
105 dietary treatment, a food frequency questionnaire and a 24-h recall questionnaire were administered
106 to each volunteer by a dietitian. These two tools allowed to extrapolate the “weekly cumulative
107 frequency of food” and the “component intake” data, respectively (Table 1), by using official Italian
108 food composition databases (INRAN,
109 http://nut.entecra.it/646/tabelle_di_composizione_degli_alimenti.html and IEO, [http://www.bda-
110 ieo.it/uk/index.aspx](http://www.bda-
110 ieo.it/uk/index.aspx)). All volunteers confirmed that not remarkable changes occurred in meals and
111 medication during the two months of treatment. Additionally, a questionnaire aimed at evaluating
112 intestinal effects (bloating, meteorism, constipation, satiety, diarrhea, reflux and flatulence) was
113 administered (26). Gastrointestinal symptoms were graded from 0 (no symptoms) to 3 (severe
114 symptoms) (26). Before the treatment with durum wheat and whole-grain barley Pasta,
115 colesterolemia, body mass index, fecal microbiota and metabolome were determined.

116 **Determination of blood cholesterol**

117 The level of total cholesterol was measured on the Siemens Dimension RxL Max by using the
118 Siemens enzymatic methods (Siemens Medical Solution Diagnostics, Tarrytown, NY). LDL- and
119 HDL-cholesterol level was estimated by using the Friedewald equation (28) for value below 300
120 mg/dl.

121 **Collection of fecal samples**

122 Each volunteer had fasted overnight, and fecal sample was collected in the morning pre-prandial.
123 Fecal samples were collected on three different days of the same week. After collection, samples
124 were immediately mixed with RNA later (Sigma-Aldrich, St. Louis, MO, USA) (ca. 5 g, 1:2 wt/vol)
125 or Amies Transport medium (Oxoid LTD, Basingstoke, Hampshire, England) (ca. 15 g, 1:1 wt/wt),
126 under anaerobic conditions (AnaeroGen, Oxoid LTD, Basingstoke, Hampshire, England). Fecal
127 samples suspended in RNA later were stored at -80°C for further RNA and metabolomic analyses.
128 Samples diluted with Amies Transport medium were immediately subjected to plate counts and
129 analysis by Biolog system.

130 **RNA extraction from fecal samples**

131 An aliquot of ca. 200 mg of fecal sample diluted in RNA later was used for RNA extraction with
132 the Stool total RNA purification kit (Norgen Biotek Corp., Ontario, Canada, USA). Quality and
133 concentration of RNA extracts were determined using 1% agarose-0.5X TBE gels and
134 spectrophotometric measurements at 260, 280 and 230 nm through the NanoDrop ND-1000
135 Spectrophotometer. Total RNA extracted (ca. 2.5 μg) was transcribed to cDNA using random
136 examers and the Tetro cDNA synthesis kit from Bioline (Bioline USA Inc, Tanunton, MA, USA),
137 according to the manufacturer's instructions (29).

138 **Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) and data analyses**

139 For each volunteer, the three cDNA samples were pooled and used for bTEFAP analysis. Pooled
140 samples cDNA were analyzed for each subject. bTEFAP was performed by Research and Testing
141 Laboratories (Lubbock, TX), according to standard laboratory procedures and using the 454 FLX

Sequencer (454 Life Sciences, Branford, CT, USA). Primers forward 28F: GAGTTTGATCNTGGCTCAG and reverse 519R: GTNTTACNGCGGCKGCTG, based upon the V1–V3 region (*Escherichia coli* position 27–519) of the 16 S rRNA gene, were used (30). The bTEFAP procedures were performed based upon RTL protocols <http://www.researchandtesting.com> (Research and Testing Laboratories, Lubbock, TX). Raw sequence data were screened, trimmed and filtered with default settings, using the QIIME pipeline version 1.4.0 (<http://qiime.sourceforge.net>). Chimeras were excluded by using the B2C2 (<http://www.researchandtesting.com/B2C2.html>) (31). Sequences less than 250 bp were removed. The average length of the sequences was 484 bp. Sequences are available at the <http://www.researchandtesting.com/docs>. FASTA sequences for each sample, without chimeras, were evaluated using BLASTn against the database derived from GenBank (<http://ncbi.nlm.nih.gov>) (32).

Bioinformatics and data analysis

The sequences were first clustered into Operational Taxonomic Unit (OTU) clusters with 97% identity (3% divergence), using USEARCH (33). To determine the identities of bacteria, sequences were first queried, using a distributed BLASTn.NET algorithm (33) against the database of high-quality 16S bacterial sequences that derived from NCBI. Database sequences were characterized as high quality based on criteria, which were originally described by Ribosomal Database Project (RDP, v10.28) (34).

Alpha diversity (rarefaction, Good's coverage, Chao1 richness and Shannon diversity indices) and beta diversity measures were calculated and plotted using QIIME. Diversity was examined from two perspectives. First, overall richness (i.e., number of distinct organisms present within the microbiome) (alpha diversity), was expressed as the number of OTU, and was quantified using the

Chao1 richness estimator: $S_{\text{chao1}} = S_{\text{obs}} + \frac{n_1(n_1-1)}{2(n_2+1)}$

where n_i is the number of OTU with abundance i .

166 Second, overall diversity (which is determined by both richness and evenness, the distribution of
167 abundance among distinct taxa) was expressed as Shannon Diversity. Shannon diversity (H') is
168 calculated using: $H' = -\sum_{i=1}^R p_i \ln(p_i)$

169 where R is richness and p_i is the relative abundance of the i th OTU.

170 Measures of diversity were screened for group differences using an analysis of variance (ANOVA).

171 Multivariate differences among groups were evaluated with "Permutational Multivariate Analysis
172 of Variance Using Distance Matrices," function `adonis` (35). For ADONIS, distances among
173 samples were calculated using un-weighted or weighted UniFrac, and then an ANOVA-like
174 simulation was conducted to test for group differences. In addition, multivariate differences were
175 assessed using "Analysis of Similarities," function `anosim` (35). Sequence data were processed
176 using a Research and Testing pipeline that is described at

177 http://www.researchandtesting.com/docs/Data_Analysis_Methodology.pdf. Spearman correlations
178 were computed between OTU and metabolite concentration. All analyses were conducting in R,
179 using the `vegan` (35), `labdsv` (36), `DESeq2` (37), and `phyloseq` (38) packages.

180 **Community-level catabolic profiles (CLCP)**

181 Carbon source utilization patterns of the fecal microbiota were assessed using Biolog 96-well Eco
182 micro-plates (Biolog, Inc., Hayward, CA, USA) (39). Micro-plates contained 31 different carbon
183 sources (carbohydrates, carboxylic acids, polymers, amino acids, amines, and miscellaneous
184 substrates) in triplicate. Five grams of feces diluted with Amies Transposrt medium (1:1) were
185 homogenized in a filter bag with 45 mL of sterile sodium chloride (0.9% (wt/vol)) solution (Classic
186 Blender) to remove solid particulate of feces. The homogenized feces were centrifuged at 11,000
187 RPM for 15 min at 4°C. The pellet was washed with 50 mM Tris-HCl (pH 7.0), then with sterile
188 sodium chloride solution and centrifuged at 11,000 RPM for 15 min at 4°C. The cellular suspension
189 was diluted (1:10) into the sterile sodium chloride solution and, subsequently, centrifuged at 2000
190 RPM for 2 min at 4°C. The cellular suspension was diluted (1:20) into sterile chloride solution and
191 dispensed (150 μ L) into each of the 96 wells of the Biolog Eco micro-plates. The micro-plates were

192 incubated at 37°C in the dark, under anaerobic conditions and slowly stirring. The color
193 development was measured at 590 nm every 24 h with a micro-plate reader (Biolog Microstation).
194 Three indices were determined (40). Shannon's diversity (H'), indicating the substrate utilization
195 pattern, was calculated as follows:

$$196 \quad H' = - \sum p_i \ln(p_i) \quad (1)$$

197 where p_i is the ratio of the activity of a particular substrate to the sums of activities of all substrates
198 at 120 h. Substrate richness (S), measuring the number of different substrates used, was calculated
199 as the number of wells with a corrected absorbance higher than 0.25. Substrate evenness (E) was
200 defined as the equitability of activities across all utilized substrates:

$$201 \quad E = H' / \log S \quad (2)$$

202 Enumeration of cultivable bacteria

203 Diluted fecal samples (20 g) were mixed with 80 ml sterilized physiological solution and
204 homogenized. Counts of viable bacterial cells were carried out as described by De Angelis et al.
205 (41). The following selective media were used: Wilkins-Chalgren anaerobe agar (total anaerobes);
206 MRS agar (*Enterococcus* and *Lactobacillus*); Slanetz and Bartley (*Enterococcus*); Rogosa agar,
207 plus 1.32 ml/l of glacial acetic acid (*Lactobacillus*); M17 (*Lactococcus* and *Streptococcus*); Baird
208 Parker (*Staphylococcus*); Wilkins-Chalgren anaerobe agar, plus GN selective supplements and
209 sheep blood defibrinated (*Bacteroides*, *Porphyromonas* and *Prevotella*); MacConkey agar No2
210 (*Enterobacteriaceae*); Chromocult (total coliform) (Merk, Darmstadt, Germany, Europe); GSP agar
211 (Sigma-Aldrich, St. Louis, MO, USA), plus penicillin-G (60 g/l) (*Pseudomonas*, *Alcaligenes* and
212 *Aeromonas*); *Bifidobacterium* agar modified (*Bifidobacterium*) (Becton Dickinson, Le Pont de
213 Claix, SA, France); and Hoyle medium (*Corynebacterium*). Except for *Bifidobacterium* agar
214 modified, Chromocult and GSP agar, all media were purchased by Oxoid Ltd (Basingstoke,
215 Hampshire, England).

216 Fecal concentration of free amino acids

217 FAA of fecal samples were analyzed through the Biochrom 30 series amino acid analyzer
218 (Biochrom Ltd., Cambridge Science Park, England) with a sodium cation-exchange column (20 by
219 0.46 cm (inner diameter)). A mixture of amino acids at known concentrations (Sigma Chemical Co.,
220 Milan, Italy) was added with cysteic acid, methionine sulfoxide, methionine sulfone, tryptophan,
221 ornithine, glutamic acid, and γ -amino-butyric acid and used as standard. Proteins and peptides in the
222 fecal samples were precipitated by addition of 5% (vol/vol) cold solid sulfosalicylic acid, holding
223 the samples at 4°C for 1 h, and centrifuging at 15,000 x g for 15 min. The supernatant was filtered
224 through a 0.22- μ m-pore-size filter and when necessary diluted, with sodium citrate (0.2 M, pH 2.2)
225 loading buffer. Amino acids were post-column derivatized with ninhydrin reagent and detected by
226 absorbance at 440 (proline and hydroxyproline) or 570 (all the other amino acids) nm.

227 **Gas-chromatography mass spectrometry-solid-phase microextraction (GC-MS/SPME)**
228 **analysis of fecal volatile compounds**

229 After preconditioning, according to the manufacturer's instructions, a
230 polydimethylsiloxane/Divinylbenzene fiber (65 μ m) and a manual solid phase micro-extraction
231 (SPME) holder (Supelco Inc., Bellefonte, PA, USA) were used. Before headspace sampling, the
232 fiber was exposed to GC inlet for 1 h for thermal desorption at 250°C. Three grams of fecal sample
233 were placed into 10 ml glass vials and added of 10 μ l of 4-methyl-2-pentanol (final concentration of
234 33 mg/l), as the internal standard. Samples were then equilibrated for 10 min at 40°C. SPME fiber
235 was exposed to each sample for 40 min. Both equilibration and absorption phases were carried out
236 with stirring. The fiber was then inserted into the injection port of the gas chromatograph for 10 min
237 of sample desorption. GC-MS analyses were carried out with an Agilent 7890A gas chromatograph
238 (Agilent Technologies, Palo Alto, CA) coupled to an Agilent 5975C mass selective detector
239 operating in electron impact mode (ionization voltage, 70 eV). A Supelcowax 10 capillary column
240 (length, 60 m; inside diameter, 0.32 mm; Supelco, Bellefonte, PA) was used. The temperature
241 program was 50°C for 1 min, followed by an increase at a rate of 4.5°C/min to 65°C, an increase at

242 a rate of 10°C/min to 230°C, and then 230°C for 25 min. The injector, interface, and ion source
243 temperatures were 250, 250, and 230°C, respectively. The mass-to-charge ratio interval was 30 to
244 350 Da at a rate of 2.9 scans per sec. Injection was carried out in splitless mode, and helium (flow
245 rate, 1 ml/min) was used as the carrier gas. Molecules were identified based on comparison of their
246 retention times with those of pure compounds (Sigma-Aldrich, Milan, Italy). Identities were
247 confirmed by searching mass spectra in the available databases (NIST, version 2005; Wiley, version
248 1996). Quantitative data for the compounds identified were obtained by interpolation of the relative
249 areas versus the internal standard area (42). All the GC-MS/SPME raw files were converted to
250 netCDF format via Chemstation (Agilent Technologies, USA) and subsequently processed by the
251 XCMS toolbox (<http://metlin.scripps.edu/download/>). XCMS software allows automatic and
252 simultaneous retention time alignment, matched filtration, peak detection, and peak matching. GC-
253 MS/SPME data were organized into matrix for subsequent statistical analysis.

254 **Statistical analysis**

255 Culture dependent data were obtained at least in triplicates. The analysis of variance (ANOVA) was
256 carried out on transformed data followed by separation of means with Tukey's HSD, using the
257 statistical software Statistica for Windows (Statistica 6.0 per Windows 1998, StatSoft, Vigonza,
258 Italy). Letters indicate significant different groups ($P < 0.05$) by Tukey's test. In order to identify
259 differences between HS and HSB samples, GC/MS/SPME data were analyzed by Canonical
260 discriminant Analysis of Principal Coordinates (41). The total variance obtained in the principal
261 coordinates used to perform the CAP was higher than 80% for all the samples. Significance testing
262 was carried out using 999 permutations. The correctly performed permutation test assigns ca. 90%
263 of the samples. Moreover, models based on projection on latent structures (PLS) in its discriminant
264 (DA) version were built based on the normalized concentration of the significant molecules
265 identified (43). Metabolically active bacterial families/genera and fecal volatile compounds were

266 analyzed by Principal Component Analysis (PCA) using the statistical software Statistica for
267 Windows (Statistica 6.0 per Windows 1998, StatSoft).

268 **Nucleotide sequence accession number**

269 The sequence data were submitted to the Sequence Read Archive database of the National Center
270 for Biotechnology Information under accession no. PRJNA290897.

271 **RESULTS**

272 **Diet and clinical evaluation**

273 In this study, the diet was monitored for two months before starting the administration of durum
274 wheat flour and whole-grain barley Pasta containing the minimum recommended intake (3 g) of β -
275 glucans. This was done to ascertain that every volunteer consumed equivalent amounts of
276 carbohydrates, total protein and fat. The only statistically ($P < 0.05$) difference in the diet, before and
277 after administration of durum wheat flour and whole-grain barley Pasta, was the amount of total
278 fibers (Table 1). All volunteers well tolerated barley flour including β -glucans and no statistical
279 ($P > 0.05$) effects regarding bloating, abdominal pain score, flatulence, frequency or consistency of
280 evacuations of feces were observed (Table S1). The observed reduction of non-HDL cholesterol
281 confirmed the European Food Safety Authority healthy claim. The estimation of cholesterol was
282 used as an internal control to validate the adherence of each volunteer to the diet and, consequently,
283 the consistency of the study.

284 **Richness and diversity of the fecal microbiota based on 16S rRNA gene sequencing data** 285 **analysis**

286 Total metabolically active bacteria from fecal samples of healthy subjects before (HS) and after
287 (HSB) administration of durum wheat flour and whole-grain barley Pasta were analyzed by
288 pyrosequencing of 16S rRNA gene. After quality control, pyrosequencing analysis yielded 156,563
289 total bacterial reads sequences with a mean of 3010 (ranged from 1146 to 5621) for sample. The
290 metabolically active bacterial community was analyzed by rarefaction curves (Fig. S1), estimated

Operational taxonomic units (OTU), richness estimator (Chao 1) and diversity index (Shannon). The Good's Estimated Sample Coverage was ca. 97%. The mean number of estimated OTU of 127.19 vs 132 ($P=0.605$) for HS and HSB, respectively. According to OTU values, the mean values of Chao1 (152 vs 160.8) and Shannon index (3.27 vs 3.3) values were not significantly different ($P=0.466$; $P=0.794$ for Chao1 and Shannon index, respectively) between HS and HSB (Fig. S2). According to alpha diversity values, the three phylogeny-based beta-diversity measures did not show clear separation between the microbiota composition of HS and HSB in weighted and unweighted UniFrac distance principle coordinate analysis plots (Fig. 1; Fig. S3). Besides, Adonis statistical test indicated no significant ($P=0.199$) differences between the microbial diversity of HS and HSB. However, ANOSIM results, which were based on weighted UniFrac testing for multivariate difference, differed ($P=0.04$; TestStat 0.05) between HS and HSB. Overall, seven phyla (*Actinobacteria*, *Bacteroidetes*, *Firmicutes*, *Fusobacteria*, *Lentisphaerae*, *Proteobacteria* and *Verrucomicrobia*) and one candidate division (TM7) were identified (Fig. S4). However, *Firmicutes* and *Bacteroidetes* represented more than 85% of all 16S rRNA sequences. No significant ($P>0.05$) differences were found for the phyla relative abundances between HS and HSB. The only exception was the phylum *Fusobacteria*, which was higher in HS compared to HSB (average relative abundance of 3.06 vs 1.85%, $P=0.019$).

According to alpha and beta-diversity and considering the 35 most dominant OTU (representing 95% of the total microbiota) of all fecal samples, HS and HSB volunteers were variously distributed (Fig. 2). Compared to fecal microbiota of HS, only few statistically ($P<0.05$) differences were detected (Table 2). HSB samples showed the highest relative abundance of *Clostridiaceae* (*Clostridium orbiscindens*; *Clostridium* sp.), *Lachnospiraceae* (*Roseburia hominis*), *Ruminococcus* sp. Other *Ruminococcaceae* (*Faecalibacterium prausnitzii* and *Faecalibacterium* sp.), *Dialister invisus* and *Fusobacteriaceae* (*Fusobacterium*) were the lowest in HSB.

OTU correlation

OTU correlation was investigated considering family- (Fig. 3A,B) or genus-level (Fig. 3C,D) taxonomic assignments and significant correlations at $FDR < 0.050$. Several family positive correlations were always found (e.g., *Coriobacteriaceae* and *Streptococcaceae*; *Porphyromonadaceae* and *Clostridiaceae*). Other positive correlations were lost in HSB compared to HS (e.g. *Eubacteriaceae* with *Coriobacteriaceae*, *Oscillospiraceae* and *Streptococcaceae*). Similar trend was detected also at genus-level. The only exception was for *Bacteroides*, which showed an increased number of positive correlations in HSB compared to HS.

Community level catabolic profiles and cultivable bacteria

The substrate utilization pattern (H' index) and substrate richness (S index) values were calculated (Fig. 4). Compared to HS, the H and S indices of HSB decreased. The E index, which measures the statistical significance (equitability) of the H' and S index values, confirmed the above-described significant ($P < 0.05$) differences.

Selective media were used to enumerate cultivable bacteria (Table 3). Compared to HS, HSB showed a lower ($P=0.05$) number of total anaerobes. The median values of presumptive *Lactobacillus* was lower than those found for HSB. Other significant ($P < 0.05$) differences concerned the number of presumptive *Bacteroides*, *Porphyromonas* and *Prevotella*, *Enterobacteria*, total coliforms and *Pseudomonas*, *Alcaligenes* and *Aeromonas*, which were the lowest in HSB fecal samples.

The fecal metabolome

Compared to HS, fecal samples of HSB had lower ($P < 0.05$) levels of some FAA (Pro, Trp, Thr, and Arg) and metabolites from the catabolism of FAA (γ -amino butyric acid) (Fig. S5). The levels of some volatile organic compounds (VOC), which was detected in fecal samples of HS, markedly differed in HSB (Fig. 5A; Fig. S6). Compared to HS, fecal samples of HSB showed increased content of several short chain fatty acids (SCFA) (2-methyl-propanoic acid, acetic acid, butanoic acid and propanoic acid) (Fig. 5B). Pentanoic acid was the only SCFA found at the highest level in

341 HS. The other statistically significant differences for VOC regarded the levels of phenylethyl
342 alcohol, benzaldehyde, indole, 2,3-butanedione, 6-methyl-5-hepten-2-one and acetophenone, which
343 were the highest in HSB. FAA and GC-MS/SPME data were also analyzed using the Principal
344 Component Analysis (PCA). The discrimination of fecal samples between HS and HSB was evident
345 (Fig. S7).

346 OTU-metabolite correlations

347 Correlations between metabolically active bacterial families/genera and metabolome data (FAA and
348 VOC) were found (Fig. 6). *Coriobacteriaceae*, *Streptococcaceae*, *Faecalibacterium*,
349 *Ruminococcaceae* and *Ruminococcus* were positively correlated with hexanoic and propanoic acids.
350 Other positive correlations were found for *Ruminococcaceae* and Tpr and γ -amino-butyric acid, and
351 *Ruminococcus* and Tpr, γ -amino-butyric acid, acetic and butanoic acids. Hexanoic acid was also
352 positively correlated with *Parabacteroides*, *Clostridiaceae* and *Clostridium*. *Bacteroidaceae*,
353 *Bacteroides* and *Alcaligenaceae* were positively correlated with Tpr, acetic, butanoic, and
354 propanoic acids, NH₃, indole, Arg, acetophenone and benzaldehyde. *Roseburia* and *Lachnospiraceae*
355 showed various positive correlations, including Thr, γ -amino-butyric acid, acetic acid, butanoic
356 acid, NH₃, indole, propanoic acid, phenyl ethyl alcohol and 2,3-butanedione.

357 DISCUSSION

358 This is one of the few studies showing the effects of durum wheat flour and whole-grain barley
359 Pasta on the human fecal microbiota and metabolome, using a meta-omics approach. As shown
360 through pyrosequencing analysis, the intervention with durum flour wheat and whole-grain barley
361 Pasta, resulting in the ingestion of 3 g/day of β -glucans, did not affect the values of alpha and beta
362 diversity. Previously, high-throughput sequencing techniques revealed that alpha diversity
363 decreased with dietary supplementation of β -glucans from sea cucumber (*Apostichopus japonicas*)
364 (44) and mirror carp (*Cyprinus carpio*) (45). The phylogenetic composition of the analyzed samples
365 confirms that the Firmicutes and Bacteroidetes phyla constitute the most abundant bacterial OTUs

366 of human intestinal microbiota. The composition of the main bacterial phyla (*Firmicutes* and
367 *Bacteroidetes*) within the enrolled volunteers was variously affected, without an unique statistically
368 significant trend. According to the 16S rRNA gene-based high-throughput sequencing, wide
369 variation among individuals was found (46, 47). *Clostridiaceae* (*Clostridium orbiscindens*,
370 *Clostridium* sp.), *Roseburia hominis* and *Ruminococcus* sp. increased following the intervention.
371 Previously, it was shown that barley and oat β -glucans induced clostridial cluster IX populations
372 and *Clostridium histolyticum* subgroup during *in vitro* fermentation by human fecal microbiota (48).
373 On the contrary, oat β -glucans did not favor the growth of *Clostridium* sp. in SHIME and C57BL/6J
374 mice models (21, 24, 49). However, several discrepancies between the different studies could be
375 due to the different models and methods used. *Faecalibacterium prausnitzii*, *Faecalibacterium* sp.
376 and *Dialister invisus* decreased following the diet intervention with barley β -glucans. A similar
377 trend was found for the genus *Fusobacterium*, belonging to *Fusobacteria*. Based on OTU
378 correlations, β -glucans negatively impacted on bacterial interactions.

379 The positive bacterial interactions also decreased during dietary supplementation with β -glucans
380 from sea cucumber (44). In agreement, the community level catabolic profiles showed decreased
381 substrate utilization pattern (H' index) and Shannon index after diet intervention with barley β -
382 glucans. All these results indicated a low metabolic diversity. Culture-dependent methods showed
383 that diet intervention with whole-grain barley markedly decreased the total number of fecal
384 anaerobic cultivable bacteria. Decreased levels of cultivable anaerobes were also found during *in*
385 *vitro* fermentation of oat β -glucans by human fecal slurry (20). According to the *in vitro* study of
386 Hughes et al. (48), cultivable presumptive thermophilic and mesophilic *Lactobacillus* increased
387 following diet intervention with barley β -glucans. No positive effects were observed regarding the
388 genus *Bifidobacterium*. A randomized, placebo-controlled, double-blind human intervention trial
389 showed that cultivable fecal lactobacilli of 26 healthy volunteers were not affected by 0.75 g of
390 barley β -glucans (26). The same study showed a statistically significant increase of the cell density
391 of bifidobacteria. After grouping volunteers according to age, a significant bifidogenic effect was

392 detected only in subjects older than 50 years. The administration of 3 g/day of β -glucans to 33
393 polypectomized patients showed no effects on the fecal cultivable lactobacilli and bifidobacteria
394 (27). An increased level of lactobacilli was found in animal models after barley or oat containing
395 diet, especially using high-viscosity β -glucans (22, 23, 24). At the same time, oat product based diet
396 or β -glucans from *Laminaria digitata*, *Laminaria hyperborea* and *Saccharomyces cerevisiae* did not
397 increase the levels of lactobacilli in pigs and rats (25, 50). Taken together, these results suggested
398 that the prebiotic potential of whole-grain barley/ β -glucans was not always reproducible *in vivo*.
399 The complex biochemical interactions and antagonistic activities within the intestinal microbiota
400 prior treatment might be responsible for the different response to β -glucans enriched diet.
401 Presumptive cultivable *Bacteroides*, *Porphyromonas* and *Prevotella* decreased following the diet
402 intervention with barley β -glucans. Overall, abundance of *Prevotella* is higher in humans which
403 consume more vegetable based diet (14). During *in vitro* fermentation, *Prevotella-Bacteroides*
404 increased only with low molecular weight β -glucans (48). Cultivable *Bacteroides* decreased in
405 SHIME model after oat bran feeding (21), while no significant differences were found in rats after
406 feeding with products enriched of oat fiber (50). A barley reach diet was associated with reduced
407 cultivable *Bacteroides* in the intestinal tract of rats (22). According to this study, cultivable
408 *Bacteroides* were negatively affected in polypectomized patients after intake of barley β -glucans
409 (27). *In vitro* and animal trials support that *Enterobacteriaceae* could not utilize β -glucans (20, 25,
410 50). According to *in vitro* and animal trials, this study showed a significant reduction of cultivable
411 *Enterobacteriaceae* and total coliforms. Similar trend was found in administration of 3 g/day of β -
412 glucans to 33 polypectomized patients (27). On the contrary, small amounts of β -glucans (0.75)
413 were not effective to decrease total cultivable coliforms or *Escherichia coli* (26). First, this study
414 showed that cell density of cultivable *Pseudomonas*, *Alcaligenes* and *Aeromonas* markedly
415 decreased after the diet intervention with Pasta enriched of barley β -glucans.

416 *In vitro* and animal trials support that high barley β -glucans consumption is associated with a
417 significant increase of the synthesis of SCFA (46, 49, 50). This study confirmed the previous GC-

MS data showing a noticeable increase of 2-methyl-propanoic acid, acetic acid, butanoic (butyric) acid and propanoic (propionic) acid after the diet intervention with durum wheat flour and whole-grain barley Pasta. SCFA induce positive gastrointestinal and systemic effects (51). SCFA are also important modulators of the host immune function (52). Acetate is used as energy source for liver and peripheral tissues, and acts as signaling molecules in gluconeogenesis and lipogenesis (53). Propionate serves as precursor for gluconeogenesis and it reduces the synthesis of hepatic cholesterol (54). Propionate was also associated with a decrease of insulin secretion in pancreatic islet cells of rats (55). Butyric acid serves as the main energy source for colonocytes and protects from inflammation (56, 57). Butyrate affects also the regulation of apoptosis and cellular proliferation, resulting in reduced risk of colon cancer (58). BCFA (e.g., iso-butyrate and iso-valerate) were not affected by whole-grain barley, indicating that the highest synthesis of SCFA was obtained without increasing undesirable protein fermentation (44). Previously, it was demonstrated that the intake of dietary fibers or symbiotic foods (e.g., fructooligosaccharides, *Lactobacillus helveticus* and *Bifidobacterium longum*) leads to a modulation of the gut metabolic activities with an increase of SCFA (59-61). Previously, *in vitro* data shows that barley and oat β -glucans or other oligosaccharides support the growth of *Clostridia* strains which synthesize acetate and butyrate (62, 63). *Bacteroides* strains are propionate producers by the succinate pathway (64) and they were positively correlated with propionic acid.

This study highlighted some *in vivo* effects of whole-grain barley towards fecal microbiota and metabolome. Whole-grain barley appeared to be effective in the modulation of the composition and the metabolic pathways of the intestinal microbiota, leading to an increased level of SCFA.

Acknowledgements

This work was funded by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), Ministero dello Sviluppo Economico and Fondo Europeo di Sviluppo Regionale (P.O.N. Ricerca e Competitività" 2007 – 2013 per le Regioni della Convergenza, project code

PON02_00657_00186_2937475/1 - PROALIFUN), ASSE I – Sostegno ai mutamenti strutturali – Obiettivo Operativo: “Reti per il rafforzamento del potenziale scientifico-tecnologico delle Regioni della Convergenza”– Azione I: ”Distretti di Alta Tecnologia e relative Reti”). We thank Maria Piccolo (Department of Soil, Plant and Food Sciences, University of Bari Aldo Moro, Bari, Italy) and Giuseppe Dalfino and Stella Diamante (*DETO*, Nephrology Unit - University of Bari Aldo Moro, Bari) for technical assistance.

Conflict of Interest Statement: None

REFERENCES

1. **Food and Drug Administration, HHS.** 2005. Food labelling: health claims; soluble dietary fiber from certain foods and coronary heart disease. Fed Regist **70**:76150–7662.
2. **Food and Drug Administration, HHS.** 2008. Food labeling: health claims; soluble fiber from certain foods and risk of coronary heart disease. Final rule. Fed Regist **73**:47828–47829.
3. **European Food Safety Authority, EFSA.** 2010. Panel on dietetic products, nutrition and allergies. Scientific opinion on dietary reference values for carbohydrates and dietary fibre. EFSA J.
4. **Tosh SM.** 2013. Review of human studies investigating the post-prandial blood-glucose lowering ability of oat and barley food products. Eur J Clin Nutr **67**:310–317.
5. **Cloetens L, Ulmius M, Johansson-Persson A, Akesson B, Onning G.** 2012. Role of dietary beta-glucans in the prevention of the metabolic syndrome. Nutr Rev **70**:444–458.
6. **Brown L, Rosner B, Willett WW, Sacks FM.** 1999. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr **69**:30–42.
7. **Bourdon I, Yokoyama W, Davis P, Hudson C, Backus R, Richter D, Knuckles B, Schneeman BO.** 1999. Postprandial lipid, glucose, insulin, and cholecystokinin responses in men fed barley Pasta enriched with β -glucan. Am J Clin Nutr **69**:55–63.

- 468 8. **Lia A, Hallmans G, Sandberg AS, Sundberg B, Aman P, Andersson H.** 1995. Oat
469 glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol
470 excretion in ileostomy subjects. *Am J Clin Nutr* **62**:1245–1251.
- 471 9. **Glore SR, Van Treeck D, Knehans AW, Guild M.** 1994. Soluble fiber and serum
472 lipids: a literature review. *J Am Diet Assoc* **94**:425–436.
- 473 10. **Bell S, Goldman VM, Bistrrian BR, Arnold AH, Ostroff G, Forse RA.** 1999. Effect of
474 beta-glucan from oats and yeast on serum lipids. *Crit Rev Food Sci Nutr* **39**:189–202.
- 475 11. **Anderson JW, Deakins DA, Floore TL, Smith BM, Whitis SE.** 1990. Dietary fiber and
476 coronary heart disease. *Crit Rev Food Sci Nutr* **29**:95–147.
- 477 12. **Karlsson F, Tremaroli V, Nielsen J, Backhed F.** 2013. Assessing the human gut
478 microbiota in metabolic diseases. *Diabetes* **62**:3341–3349.
- 479 13. **Zhang PP, Hu XZ, Zhen HM, Xu C, Fan MT.** 2012. Oat beta-glucan increased
480 ATPases activity and energy charge in small intestine of rats. *J Agric Food Chem*
481 **60**:9822–9827.
- 482 14. **Montemurno E, Cosola C, Dalfino G, Daidone G, De Angelis M, Gobbetti M,**
483 **Gesualdo L.** 2014. What would you like to eat, mr CKD microbiota? A mediterranean
484 diet, please! *Kidney Blood Press Res* **39**:114–123.
- 485 15. **Flint HJ, Duncan SH, Scott KP, Louis P.** 2007. Interactions and competition within the
486 microbial community of the human colon links between diet and health. *Environ*
487 *Microbiol* **9**:1101–1111.
- 488 16. **Bergman EN.** 1990. Energy contributions of volatile fatty acids from the gastrointestinal
489 tract in various species. *Physiol Rev* **70**:567–590.
- 490 17. **Bernalier-Donadille A.** 2012. Fermentative metabolism by the human gut microbiota.
491 *Gastroenterol Clin Biol* **34**:16–22.

- 492 18. **Bäckhed F, Hao D, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF,**
493 **Gordon JI.** 2004. The gut microbiota as an environmental factor that regulates fat
494 storage. *Proc Natl Acad Sci USA* **101**:15718–15723.
- 495 19. **Bindels LB, Delzenne NM, Cani PD, Walter J.** 2015. Towards a more comprehensive
496 concept for prebiotics. *Nat Rev Gastroenterol Hepatol* **12**:303–310.
- 497 20. **Jaskari J, Kontula P, Siitonen A, Jousimies-Somer H, Mattila-Sandholm T,**
498 **Poutanen K.** 1998. Oat β -glucan and xylan hydrolysates as selective substrates for
499 *Bifidobacterium* and *Lactobacillus* strains. *Appl Microbiol Biotechnol* **49**:175–181.
- 500 21. **Kontula P, Jaskari J, Nollet L, De Smet I, von Wright A, Poutanen K, Mattila-**
501 **Sandholm T.** 1998. The colonization of a simulator of the human intestinal microbial
502 ecosystem by a probiotic strain fed on a fermented oat bran product effects on the
503 gastrointestinal microbiota. *Appl Microbiol Biotechnol* **50**:246–252.
- 504 22. **Dongowski G, Huth M, Gebhardt E, Flamme W.** 2002. Dietary fiber-rich barley
505 products beneficially affect the intestinal tract of rats. *J Nutr* **132**:3704–3714.
- 506 23. **Snart J, Bibiloni R, Grayson T, Lay C, Zhang H, Allison GE, Laverdiere JK,**
507 **Temelli F, Vasanthan T, Bell R, Tannock GW.** 2006. Supplementation of the diet with
508 high-viscosity beta-glucan results in enrichment for lactobacilli in the rat cecum. *Appl*
509 *Environ Microbiol* **72**:1925–1931.
- 510 24. **Zhou AL, Hergert N, Rompato G, Lefevre M.** 2014. Whole grain oats improve insulin
511 sensitivity and plasma cholesterol profile and modify gut microbiota composition in
512 C57BL/6J mice. *J Nutr* **145**:222–230.
- 513 25. **Murphy P, Dal Bello F, O'Doherty J, Arendt EK, Sweeney T, Coffey A.** 2013.
514 Analysis of bacterial community shifts in the gastrointestinal tract of pigs fed diets
515 supplemented with β -glucan from *Laminaria digitata*, *Laminaria hyperborea* and
516 *Saccharomyces cerevisiae*. *Animal* **7**:1079–1087.

- 517 26. Mitsoua EK, Panopouloub N, Turunena K, Spiliotis V, Kyriacou A. 2010. Prebiotic
518 potential of barley derived β -glucan at low intake levels: a randomised, double-blinded,
519 placebo-controlled clinical study. *Food Res Int* **43**:1086–1092.
- 520 27. Turunen K, Tsouvelakidou E, Nomikos T, Mountzouris KC, Karamanolis D,
521 Triantafyllidis J, Kyriacou A. 2011. Impact of beta-glucan on the fecal microbiota of
522 polypectomized patients: a pilot study. *Anaerobe* **17**:403–406.
- 523 28. Friedewald WT, Levy RI, Fredrickson DS. 1972. Estimation of the concentration of
524 low-density lipoprotein cholesterol in plasma, without use of the preparative
525 ultracentrifuge. *Clin Chem* **18**:499–502.
- 526 29. Gowen CM, Fong SS. 2010. Genome-scale metabolic model integrated with RNAseq
527 data to identify metabolic states of *Clostridium thermocellum*. *Biotechnol J* **7**:759–767.
- 528 30. Suchodolski JS, Dowd SE, Wilke V, Steiner JM, Jergens AE. 2012. 16S rRNA gene
529 pyrosequencing reveals bacterial dysbiosis in the duodenum of dogs with idiopathic
530 inflammatory bowel disease. *PLoS One* **7**:e39333.
- 531 31. Gontcharova V, Youn E, Wolcott RD, Hollister EB, Gentry TJ, Dowd SE. 2010.
532 Black box chimera check B2C2a: windows-based software for batch depletion of
533 chimeras from bacterial 16 S rRNA gene datasets. *Open Microbiol J* **4**:47–52.
- 534 32. Dowd SE, Zaragoza J, Rodriguez JR, Oliver MJ, Payton PR. 2005. Windows. NET
535 network distributed basic local alignment search toolkit WND-BLAST. *BMC*
536 *Bioinformatics* **6**:693.
- 537 33. Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST.
538 *Bioinformatics* **26**:2460–2461.
- 539 34. Cole JR, Wang Q, Cardenas E, Fish J, Chai B, Farris RJ, Kulam-Syed-Mohideen
540 AS, McGarrell DM, Marsh T, Garrity GM, Tiedje JM. 2009. The ribosomal database
541 project improved alignments and new tools for rRNA analysis. *Nucleic Acids Res*
542 **37**:141–145.

- 543 35. **Oksanen J, Blanchet FG, Kindt R, Legendre P, O'Hara RB, Simpson GL, Solymos**
544 **P, Stevens MHH, Wagner H.** 2011. *vegan: Community Ecology Package*, R package
545 version 1.17–1.
- 546 36. **Roberts DW.** 2010. *labdsv: Ordination and Multivariate Analysis for Ecology*. R
547 package version 1.4–1.
- 548 37. **Anders S, Huber W.** 2010. Differential expression analysis for sequence count data.
549 *Genome Biol* **11**:106.
- 550 38. **McMurdie PJ, Holmes S.** 2013. *phyloseq: An R package for reproducible interactive*
551 *analysis and graphics of microbiome census data*. *PLoS One*, **8**:e61217.
- 552 39. **Crecchio C, Gelsomino A, Ambrosoli R, Minatic JL, Ruggiero P.** 2004. Functional
553 and molecular responses of soil microbial communities under differing soil management
554 practices. *Soil Biol Biochem* **36**:1873–1883.
- 555 40. **Zak JC, Willing MR, Moorhead DL, Wildman HG.** 1994. Functional diversity of
556 microbial communities a quantitative approach. *Soil Biol Biochem* **26**:1101–1108.
- 557 41. **De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Siragusa S,**
558 **Serrazanetti DI, Cristofori F, Guerzoni ME, Gobbetti M, Francavilla R.** 2013.
559 Fecal microbiota and metabolome of children with autism and pervasive developmental
560 disorder not otherwise specified. *PLoS One* **8**:e76993.
- 561 42. **Ndagijimana M, Laghi L, Vitali B, Placucci G, Brigidi P, Guerzoni ME.** 2009. Effect
562 of a synbiotic food consumption on human gut metabolic profiles evaluated by 1H
563 Nuclear Magnetic Resonance spectroscopy. *Int J Food Microbiol* **13**:4147–4153.
- 564 43. **De Filippis F, Vannini L, La Stora A, Laghi L, Piombino P, Stellato G, Serrazanetti**
565 **DI, Gozzi G, Turrone S, Ferrocino I, Lazzi C, Di Cagno R, Gobbetti M, Ercolini D.**
566 2014. The same microbiota and a potentially discriminant metabolome in the saliva of
567 omnivore, ovo-lactovegetarian and vegan individuals. *PLoS One* **9**:e112373.

- 568 44. **Yang J, Xu Z, Tian X, Dong S, Peng M.** 2015. Intestinal microbiota and immune
569 related genes in sea cucumber (*Apostichopus japonicus*) response to dietary β -glucan.
570 Biochem Biophys Res Commun **23**:74–81.
- 571 45. **Kühlwein H, Merrifield DL, Rawling MD, Foey AD, Davies SJ.** 2014. Effects of
572 dietary β -1,31,6-D-glucan supplementation on growth performance, intestinal
573 morphology and haemato-immunological profile of mirror carp (*Cyprinus carpio* L.) J
574 Anim Physiol Anim Nutr Berl **98**:279–289.
- 575 46. **Yang J, Martínez I, Walter J, Keshavarzian A, Rose DJ.** 2013. *In vitro*
576 characterization of the impact of selected dietary fibers on fecal microbiota composition.
577 Anaerobe **23**:74–81.
- 578 47. **Greiner T, Bäckhed F.** 2011. Effects of the gut microbiota on obesity and glucose
579 homeostasis. Trends Endocrinol Metab **22**:117–123.
- 580 48. **Hughes SA, Shewry PR, Gibson GR, McCleary BV, Rastall RA.** 2008. *In vitro*
581 fermentation of oat and barley derived b-glucans by human fecal microbiota. FEMS
582 Microbiol Ecol **64**:482–493.
- 583 49. **Shimizu J, Tsuchihashi N, Kudoh K, Wada M, Takita T, Innami S.** 2001. Dietary
584 curdlan increases proliferation of Bifidobacteria in the cecum of rats. Biosci Biotechnol
585 Biochem **65**:466–469.
- 586 50. **Drzikova B, Dongowski G, Gebhardt E.** 2005. Dietary fibre-rich oat-based products
587 affect serum lipids, microbiota, formation of short-chain fatty acids and steroids in rats.
588 Br J Nutr **94**:1012–1025.
- 589 51. **Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ.** 2006. Colonic health
590 fermentation and short chain fatty acids. J Clin Gastroenterol **40**:235–243.
- 591 52. **Tilg H, Moschen AR.** 2014. Microbiota and diabetes: an evolving relationship. Gut **63**:
592 1513–1521.

- 593 53. **Zambell KL, Fitch MD, Fleming SE.** 2003. Acetate and butyrate are the major
594 substrates for de novo lipogenesis in rat colonic epithelial cells. *J Nutr* **133**:3509–3515.
- 595 54. **Cheng HH, Lai MH.** 2000. Fermentation of resistant rice starch produces propionate
596 reducing serum and hepatic cholesterol in rats. *J Nutr* **130**:1991–1995.
- 597 55. **Ximenes H, Hirata AE, Rocha MS, Curi R, Carpinelli AR.** 2007. Propionate inhibits
598 glucose-induced insulin secretion in isolated rat pancreatic islets. *Cell Biochem Funct*
599 **25**:173–178.
- 600 56. **Ogawa H, Iimura M, Eckmann L, Kagnoff MF.** 2004. Regulated production of the
601 chemokine CCL28 in human colon epithelium. *Am J Physiol Gastrointest Liver Physiol*
602 **287**:G1062–1069.
- 603 57. **Canani RB, Di Costanzo M, Leone L, Pedata M, Meli R, Calignano A.** 2011.
604 Potential beneficial effects of butyrate in intestinal and extra-intestinal diseases. *World J*
605 *Gastroenterol* **17**:1519–1528.
- 606 58. **Scheppach W, Bartram H, Richter F.** 1995. Role of short-chain fatty acids in the
607 prevention of colorectal cancer. *Eur J Cancer* **31**:1077–1080.
- 608 59. **Vitali B, Ndagijimana M, Cruciani F, Carnevali P, Candela M, Guerzoni ME,**
609 **Brigidi P.** 2010. Impact of a synbiotic food on the gut microbial ecology and metabolic
610 profiles. *BMC Microbiol* **10**:4.
- 611 60. **Candela M, Maccaferri S, Turrone S, Carnevali P, Brigidi P.** 2010. Functional
612 intestinal microbiome, new frontiers in prebiotic design. *Int J Food Microbiol* **140**:93–
613 101.
- 614 61. **Candela M, Biagi E, Turrone S, Maccaferri S, Figini P, Brigidi P.** 2015. Dynamic
615 efficiency of the human intestinal microbiota. *Crit Rev Microbiol* **41**:165–171.
- 616 62. **Mitsuoka T.** 1996. Intestinal flora and human health. *Asia Pac J Clin Nutr* **5**:2–9.

- 617 63. Shimizu T, Ohtani K, Hirakawa H, Ohshima K, Yamashita A, Shiba T, Ogasawara
618 N, Hattori M, Kuhara S, Hayashi H. 2002. Complete genome sequence of *Clostridium*
619 *perfringens*, an anaerobic flesh-eater. Proc Natl Acad Sci U S A **99**:996–1001.
- 620 64. Louis P, Scott KP, Duncan SH, Flint HJ. 2007. Understanding the effects of diet on
621 bacterial metabolism in the large intestine. J Appl Microbiol **102**:1197–1208.
- 622
- 623

624 **Figure legends**

625 **FIG 1** Principle Coordinate Analysis (PCoA) of metabolically active bacteria. PCoA was based on
626 weighted UniFrac analysis of all 16S rRNA gene sequences found on fecal samples of healthy
627 subject before (HS) and after two months of diet intervention (HSB) with durum wheat flour and
628 whole-grain barley Pasta.

629 **FIG 2** Heatmap summarizing the relative abundance of the 35 most dominant species in RNA
630 samples directly extracted from healthy subjects before (HS) and after (HSB) two months of diet
631 intervention with durum wheat flour and whole-grain barley Pasta. The color key defines the
632 percentages of OTU in the samples.

633 **FIG 3** Significant correlations between family (A, B) and genus (C, D) bacterial OTU before (A, C)
634 and after (B, D) two months of diet intervention with durum wheat flour and whole-grain barley
635 Pasta. The colors of the scale bar denote the nature of the correlation, with 1 indicating a perfectly
636 positive correlation (red) and -1 indicating a perfectly negative correlation (green) between two
637 microbial families or genera. Only significant correlations (FDR<0.05) are shown.

638 **FIG 4** Community level catabolic profiles. CLCP indices (utilization pattern substrate (H'),
639 substrate richness (S), and equitability (E)) of the fecal microbiota of healthy subjects before (HS)
640 and after (HSB) two months of diet intervention with durum wheat flour and whole-grain barley
641 Pasta. Data are the means of three independent experiments (n 3). The center line of each box
642 represents the median, and the top and bottom of the box represent the 75th and 25th percentiles of
643 the data, respectively. The top and bottom of the error bars represent the 5th and 95th percentiles of
644 the data, respectively. The circles in each box plot extend to the outliers of the data.

645 **FIG 5** Score (A) and loading coefficient (B) plots of Canonical Discriminant Analysis of Principal
646 Coordinates (CAP) of volatile organic metabolites in feces of healthy subjects before (HS) and after
647 (HSB) diet intervention with durum wheat flour and whole-grain barley Pasta. Compounds
648 significantly associated with the feces of HSB (negative axis) or HS samples (positive axis) Data
649 are the means of three independent experiments (n = 3).

650 **FIG 6** Significant correlations between metabolically active bacterial OTU (family and genus
651 level) and after free amino acids and volatile organic compounds after two months of diet
652 intervention with durum wheat flour and whole-grain barley Pasta. The colors of the scale bar
653 denote the nature of the correlation, with 1 indicating a perfectly positive correlation (red) and -1
654 indicating a perfectly negative correlation (green) between two microbial families or genera. Only
655 significant correlations ($FDR < 0.05$) are shown.

656

657

658 **TABLE 1.** Basic characteristics and diet of volunteers. Each healthy subject was analyzed before
 659 (HS) and after (HSB) two months of diet intervention with 100 g/day of durum wheat and whole-
 660 grain barley pasta containing 3% (wt/wt) of β -glucans.

Basic characteristics	HS	HSB
Age (years)	39 \pm 9	39 \pm 9
Male (%)	46	46
Body Mass Index (kg/m ²)	22.6 \pm 3 ^a	22.6 \pm 3 ^a
Total Cholesterol (mg/dl)	183.8 \pm 30.2 ^b	173.25 \pm 27.4 ^c
LDL Cholesterol (mg/dl)	107.4 \pm 25.2 ^b	93.25 \pm 24.5 ^c
HDL Cholesterol (mg/dl)	62.48 \pm 16.63 ^a	62.41 \pm 16.56 ^a
Weekly cumulative frequency of food	HS	HSB
Milk	50 ^a	50 ^a
Pasta	100 ^a	0 ^b
Pasta β -Glucan	0 ^a	100 ^b
Bread	97 ^a	100 ^a
Meats	85 ^a	84 ^a
Cured meats	73 ^a	68 ^a
Fish	77 ^a	81 ^a
Dairy Products	81 ^a	77 ^a
Eggs	89 ^a	84 ^a
Legumes	77 ^a	76 ^a
Leafy vegetables	100 ^a	100 ^a

Fruits	93 ^a	96 ^a
Yogurt	8 ^a	8 ^a
Sweets	59 ^a	57 ^a
Components Intake	HS	HSB
Water (g)	717.0±274.6 ^a	853.4±512.7 ^a
Protein (g)	69.9±29.5 ^a	77.6±41.7 ^a
Lipid (g)	58.3±31.3 ^a	68.7±42.2 ^a
Carbohydrate (g)	199.8±73.9 ^a	237.4±101.6 ^a
Starch (g)	130.1±54.9 ^a	151.1±70.3 ^a
Soluble sugars (g)	58.7±27.9 ^a	73.4±37.6 ^a
Alcohol (g)	7.9±13.3 ^a	6.5±12.1 ^a
Total fiber (g)	13.4±8.2 ^a	22.0±11.7 ^b
Energy (kcal)	1613.1±609.6 ^a	1894.3±908.9 ^a
Sodium (mg)	1233.3±886.5 ^a	1498.5±1180.4 ^a
Potassium (mg)	2091.7±888.6 ^a	2408.5±1433.0 ^a
Iron (mg)	11.7±20.7 ^a	8.3±6.1 ^a
Calcium (mg)	446.2±274.6 ^a	533.0±339.8 ^a
Phosphorus (mg)	986.1±705.8 ^a	940.6±625.7 ^a
Thiamine (mg)	0.7±0.3 ^a	0.9±0.8 ^a
Riboflavin (mg)	0.9±0.4 ^a	1.0±0.8 ^a
Niacin (mg)	11.5±6.3 ^a	12.7±8.5 ^a
Vit. C (mg)	64.6±39.7 ^a	179.3±340.3 ^a
Vit. E (mg)	5.0±8.9 ^a	5.8±12.1 ^a

661 ^{a-c}Values within a row with different superscript letters are significantly different (P<0.05).

662

663 **TABLE 2.** Pyrosequencing data summary.

Phylum	Family	Avg (%)	Avg (%)	p-value
		HS*	HSB	S/SB
Firmicutes	Clostridiaceae	5.26	8.08	0.019
	Eubacteriaceae	8.827	5.135	0.229
	Ruminococcaceae	31.55	23.37	0.023
Fusobacteria	Fusobacteriaceae	3.06	1.85	0.019
	Specie			
Firmicutes	<i>Clostridium orbiscindens</i>	0.22	0.68	0.045
Firmicutes	<i>Clostridium</i> sp.	2.95	4.69	0.048
	<i>Roseburia hominis</i>	0.01	0.12	0.047
Firmicutes	<i>Faecalibacterium prausnitzii</i>	12.27	6.08	0.004
	<i>Faecalibacterium</i> sp.	11.29	6.32	0.016
	<i>Ruminococcus</i> sp.	5.60	8.82	0.047
Firmicutes	<i>Dialister invisus</i>	0.52	0.13	0.034
Fusobacteria	<i>Fusobacterium</i> sp.	3.06	1.85	0.019

664 *Each healthy subject was analysed before (HS) and after (HSB) two months of diet intervention
 665 with 100 g/day of durum wheat and whole-grain barley pasta containing 3% (wt/wt) of β -glucans.
 666 Relative abundance (average value, Avg %) of predominant bacterial taxa, showing significant
 667 ($P<0.05$) differences between fecal samples of HS and HSB.

668

669

670 **TABLE 3.** Fecal cultivable bacteria of the main microbial groups.

Microbial group	Mean no. of cultivable cells, log CFU/ml (range)	
	HS*	HSB
Total anaerobes	9.80 ^a (9.33 – 9.93)	8.42 ^b (4.98 – 9.81)
<i>Lactobacillus</i> (thermophilus 42°C)	6.61 ^b (4.60 – 8.93)	7.53 ^a (4.93 – 9.16)
<i>Lactobacillus</i> (mesophilus 25°C)	6.61 ^b (3.26 – 8.98)	7.38 ^a (4.46 – 9.28)
<i>Enterococcus</i>	7.05 ^a (5.36 – 8.55)	7.29 ^a (3.90 – 9.19)
<i>Lactococcus</i> and <i>Streptococcus</i>	7.74 ^a (5.36 – 8.55)	7.57 ^a (4.25 – 9.26)
<i>Staphylococcus</i>	5.68 ^a (2.84 – 8.11)	6.14 ^a (4.38 – 8.08)
<i>Bacteroides</i> , <i>Porphyromonas</i> and <i>Prevotella</i>	9.09 ^a (3.00 – 9.92)	5.17 ^b (2.52 – 6.44)
<i>Enterobacteriaceae</i>	7.07 ^a (5.11 – 9.27)	6.11 ^b (4.19 – 7.14)
Total Coliforms	6.94 ^a (1.91 – 8.93)	6.48 ^b (1.00 – 5.32)
<i>Pseudomonas</i> , <i>Alcaligenes</i> and <i>Aeromonas</i>	6.42 ^a (1.97 – 7.95)	3.68 ^b (1.00 – 4.81)
<i>Bifidobacterium</i>	7.16 ^a (4.33 – 9.80)	6.90 ^a (4.19 – 9.09)
<i>Corynebacterium</i>	4.93 ^a (1.74 – 7.68)	5.35 ^a (2.00 – 7.17)

671 *Each healthy subject was analysed before (HS) and after (HSB) two months of diet intervention
 672 with 100 g/day of durum wheat and whole-grain barley pasta containing 3% (wt/wt) of β -glucans.

673 ^{a-b}Values within a row with different superscript letters are significantly different (P<0.05).

674

Figure 1




Figure 2




Figure 3





Figure 4

Figure 5




Figure 6

